Literature DB >> 22001865

Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury.

Tarek Moustafa1, Peter Fickert, Christoph Magnes, Christian Guelly, Andrea Thueringer, Sasa Frank, Dagmar Kratky, Wolfgang Sattler, Helga Reicher, Frank Sinner, Judith Gumhold, Dagmar Silbert, Günter Fauler, Gerald Höfler, Achim Lass, Rudolf Zechner, Michael Trauner.   

Abstract

BACKGROUND & AIMS: The liver controls central processes of lipid and bile acid homeostasis. We aimed to investigate whether alterations in lipid metabolism contribute to the pathogenesis of chronic cholestatic liver disease in mice.
METHODS: We used microarray and metabolic profiling analyses to identify alterations in systemic and hepatic lipid metabolism in mice with disruption of the gene ATP-binding cassette sub-family B member 4 (Abcb4(-/-) mice), a model of inflammation-induced cholestatic liver injury, fibrosis, and cancer.
RESULTS: Alterations in Abcb4(-/-) mice, compared with wild-type mice, included deregulation of genes that control lipid synthesis, storage, and oxidation; decreased serum levels of cholesterol and phospholipids; and reduced hepatic long-chain fatty acyl-CoAs (LCA-CoA). Feeding Abcb4(-/-) mice the side chain-modified bile acid 24-norursodeoxycholic acid (norUDCA) reversed their liver injury and fibrosis, increased serum levels of lipids, lowered phospholipase and triglyceride hydrolase activities, and restored hepatic LCA-CoA and triglyceride levels. Additional genetic and nutritional studies indicated that lipid metabolism contributed to chronic cholestatic liver injury; crossing peroxisome proliferator-activated receptor (PPAR)-α-deficient mice with Abcb4(-/-) mice (to create double knockouts) or placing Abcb4(-/-) mice on a high-fat diet protected against liver injury, with features similar to those involved in the response to norUDCA. Placing pregnant Abcb4(-/-) mice on high-fat diets prevented liver injury in their offspring. However, fenofibrate, an activator of PPARα, aggravated liver injury in Abcb4(-/-) mice.
CONCLUSIONS: Alterations in lipid metabolism contribute to the pathogenesis and progression of cholestatic liver disease in mice.
Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22001865     DOI: 10.1053/j.gastro.2011.09.051

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  47 in total

1.  Mouse models of liver fibrosis mimic human liver fibrosis of different etiologies.

Authors:  Allyson K Martínez; Luca Maroni; Marco Marzioni; Syed T Ahmed; Mena Milad; Debolina Ray; Gianfranco Alpini; Shannon S Glaser
Journal:  Curr Pathobiol Rep       Date:  2014-12-01

2.  Preventative activity of kimchi on high cholesterol diet-induced hepatic damage through regulation of lipid metabolism in LDL receptor knockout mice.

Authors:  Minji Woo; Mijeong Kim; Jeong Sook Noh; Chan Hum Park; Yeong Ok Song
Journal:  Food Sci Biotechnol       Date:  2017-12-12       Impact factor: 2.391

3.  Lipids in liver disease: looking beyond steatosis.

Authors:  Robert F Schwabe; Jacquelyn J Maher
Journal:  Gastroenterology       Date:  2011-11-19       Impact factor: 22.682

4.  A switch in the source of ATP production and a loss in capacity to perform glycolysis are hallmarks of hepatocyte failure in advance liver disease.

Authors:  Taichiro Nishikawa; Nadège Bellance; Aaron Damm; Han Bing; Zhen Zhu; Kan Handa; Mladen I Yovchev; Vasudha Sehgal; Tyler J Moss; Michael Oertel; Prahlad T Ram; Iraklis I Pipinos; Alejandro Soto-Gutierrez; Ira J Fox; Deepak Nagrath
Journal:  J Hepatol       Date:  2014-02-26       Impact factor: 25.083

Review 5.  Recent developments in diagnostics and treatment of neonatal cholestasis.

Authors:  Amy G Feldman; Ronald J Sokol
Journal:  Semin Pediatr Surg       Date:  2020-07-23       Impact factor: 2.754

Review 6.  Mouse models for liver cancer.

Authors:  Latifa Bakiri; Erwin F Wagner
Journal:  Mol Oncol       Date:  2013-02-05       Impact factor: 6.603

7.  Identification and Characterization of Fenofibrate-Induced Liver Injury.

Authors:  Jawad Ahmad; Joseph A Odin; Paul H Hayashi; Naga Chalasani; Robert J Fontana; Huiman Barnhart; Elizabeth T Cirulli; David E Kleiner; Jay H Hoofnagle
Journal:  Dig Dis Sci       Date:  2017-11-08       Impact factor: 3.199

8.  Fibrosis reduces severity of acute-on-chronic pancreatitis in humans.

Authors:  Chathur Acharya; Rachel A Cline; Deepthi Jaligama; Pawan Noel; James P Delany; Kyongtae Bae; Alessandro Furlan; Catherine J Baty; Jenny M Karlsson; Bedda L Rosario; Krutika Patel; Vivek Mishra; Chandra Dugampudi; Dhiraj Yadav; Sarah Navina; Vijay P Singh
Journal:  Gastroenterology       Date:  2013-05-15       Impact factor: 22.682

Review 9.  Animal models in primary biliary cirrhosis and primary sclerosing cholangitis.

Authors:  Marion J Pollheimer; Peter Fickert
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

10.  Sphingolipid metabolism as a marker of hepatotoxicity in drug-induced liver injury.

Authors:  Linhao Li; Hongbing Wang; Jace W Jones
Journal:  Prostaglandins Other Lipid Mediat       Date:  2020-09-30       Impact factor: 3.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.